Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fondaparinux for VTE prevention in abdominal surgery
NCT00333021Phase 3Completed
- Sponsor
- GSK
- Start
- May 2006
- Modality
- Allosteric Modulators
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of fondaparinux in venous thromboembolism (VTE) (2 arms), sponsored by GSK. Primary endpoint: Incidence of Venous Thromboembolism and Major Bleeding. Started May 2006; status: completed.
02
Drugs
fondaparinux
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00333021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00333021.